813 related articles for article (PubMed ID: 18269310)
1. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
[TBL] [Abstract][Full Text] [Related]
2. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
[TBL] [Abstract][Full Text] [Related]
3. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene.
Li C; Ominsky MS; Tan HL; Barrero M; Niu QT; Asuncion FJ; Lee E; Liu M; Simonet WS; Paszty C; Ke HZ
Bone; 2011 Dec; 49(6):1178-85. PubMed ID: 21890008
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
Li X; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Grisanti M; Dwyer D; Stouch B; Thway TM; Stolina M; Ominsky MS; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
J Bone Miner Res; 2010 Dec; 25(12):2647-56. PubMed ID: 20641040
[TBL] [Abstract][Full Text] [Related]
5. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
[TBL] [Abstract][Full Text] [Related]
6. Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice.
Yang H; Büttner A; Albiol L; Julien C; Thiele T; Figge C; Kramer I; Kneissel M; Duda GN; Checa S; Willie BM
Sci Rep; 2020 Dec; 10(1):22299. PubMed ID: 33339872
[TBL] [Abstract][Full Text] [Related]
7. TIEG and estrogen modulate SOST expression in the murine skeleton.
Subramaniam M; Pitel KS; Bruinsma ES; Monroe DG; Hawse JR
J Cell Physiol; 2018 Apr; 233(4):3540-3551. PubMed ID: 29044507
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
10. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
12. Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density.
O'Donohue AK; Xiao Y; Lee LR; Schofield T; Cheng TL; Munns CF; Baldock PA; Schindeler A
Bone; 2023 Feb; 167():116636. PubMed ID: 36462771
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin deficiency is linked to altered bone composition.
Hassler N; Roschger A; Gamsjaeger S; Kramer I; Lueger S; van Lierop A; Roschger P; Klaushofer K; Paschalis EP; Kneissel M; Papapoulos S
J Bone Miner Res; 2014 Oct; 29(10):2144-51. PubMed ID: 24753092
[TBL] [Abstract][Full Text] [Related]
14. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.
Ryan ZC; Ketha H; McNulty MS; McGee-Lawrence M; Craig TA; Grande JP; Westendorf JJ; Singh RJ; Kumar R
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6199-204. PubMed ID: 23530237
[TBL] [Abstract][Full Text] [Related]
16. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
17. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
[TBL] [Abstract][Full Text] [Related]
18. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
19. Effects of Long-Term Sclerostin Deficiency on Trabecular Bone Mass and Adaption to Limb Loading Differ in Male and Female Mice.
Albiol L; Büttner A; Pflanz D; Mikolajewicz N; Birkhold AI; Kramer I; Kneissel M; Duda GN; Checa S; Willie BM
Calcif Tissue Int; 2020 Apr; 106(4):415-430. PubMed ID: 31873756
[TBL] [Abstract][Full Text] [Related]
20. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
